Here's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 Months

Argenx's Q2 2026 global product net sales rose 60% year over year and 17% sequentially to $1.5 billion, extending its streak to 18 consecutive quarters of revenue growth. Vyvgart franchise momentum was supported by a May FDA label expansion covering all adult generalized myasthenia gravis serotypes, while CIDP adoption remains a growth opportunity. Consensus implies 23% 12-month upside, with bullish Wells Fargo and UBS targets suggesting 47% and 45% upside, respectively; however, upcoming registrational data—including empasiprubart MMN results in Q4 2026—create material clinical-trial risk.

Analysis

ARGX is transitioning from a single-indication launch story to a franchise-duration story, but the market will increasingly value incremental indications on probability-adjusted peak sales rather than headline growth. The key near-term debate is whether subcutaneous Hytrulo expands the treated population and persistence versus merely cannibalizing IV use; favorable mix and patient onboarding metrics can support upward revisions to 2027 revenue and operating-margin estimates. CIDP execution also matters disproportionately because it tests reimbursement and neurologist adoption outside the established gMG prescriber base.

The next 1-3 months are likely dominated by filing timing, payer coverage updates and evidence of prescription durability, not broad analyst-target changes. Ocular MG and myositis represent valuable whitespace, but they should not be capitalized at full value before regulators define label breadth and commercial uptake; the lack of approved alternatives raises pricing power but can also invite more restrictive utilization management. The Q4 empasiprubart MMN readout is the principal binary risk: a miss would expose concentration in Vyvgart and likely compress the premium growth multiple even if core sales remain intact.

Consensus appears too focused on revenue momentum and underweights competitive and policy risk. FcRn competitors—including UCB's Rystiggo and Johnson & Johnson's IMAAVY—can use contracting, dosing convenience and indication-specific evidence to pressure net price or share as markets mature. Conversely, ARGX's installed prescriber relationships and broad gMG label can make it the default biologic, creating a formulary advantage that is more defensible than a simple trial-by-trial comparison suggests over the next 6-18 months.

Key Decisions for Investors

• Maintain a core long ARGX only below a defined catalyst-weighted position size through the Q4 2026 MMN readout; use a 3-6 month call spread rather than outright incremental stock exposure if implied volatility is below the expected post-data move. Upside requires both clean data and sustained franchise guidance; downside is a multiple reset on a miss.
• Add to ARGX on evidence that Hytrulo drives net new patients—monitor quarterly treated-patient growth, discontinuation rates and net-price commentary rather than reported sales alone. A deceleration in patient additions despite strong revenue would falsify the penetration thesis and argue for reducing exposure.
• Use a relative-value watch: long ARGX / short UCB if ARGX demonstrates superior CIDP uptake while UCB's Rystiggo shows weaker autoimmune growth. Do not initiate without current valuation and indication-level sales data; the trade depends on confirming that competitive displacement, rather than market expansion, is occurring.
• Hedge event risk ahead of Q4 with a modest ARGX put spread financed by trimming spot exposure after a pre-readout rally. Reassess if management raises durable 2027 revenue expectations or if MMN data demonstrate clinically meaningful efficacy with a clean safety profile, either of which would invalidate a near-term downside hedge.